MSB 0.69% $1.44 mesoblast limited

Ann: Mesoblast Type A Meeting with FDA, page-522

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 17,093 Posts.
    lightbulb Created with Sketch. 2416
    "I'd like to see the data in the adults too. I think FDA knew the cells worked at least from 2020. Anyone genuinely sceptical of Ryoncil's efficacy and a true believer in the "gold standard" of randomized, controlled studies would accept the real possibility that a study in adults might not provide further efficacy and therefore they'd spot the implication of approval for children being contingent on further data in adults as unscientific nonsense right away."

    If the claims of high potency and efficacy are not confirmed in a properly controlled adult study, than the FDA are going to be sceptical about similar claims in children without a confirmatory trial, because it would be the third randomised trial to fail to show efficacy in aGVHD. That's precisely why SI hasn't done it and would prefer to push what little success he has already. Now he has no choice but to front up and do what the FDA recommended.
    Last edited by whytee: 24/10/23
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.44
Change
-0.010(0.69%)
Mkt cap ! $1.644B
Open High Low Value Volume
$1.50 $1.50 $1.43 $4.048M 2.778M

Buyers (Bids)

No. Vol. Price($)
6 26808 $1.44
 

Sellers (Offers)

Price($) Vol. No.
$1.45 16001 1
View Market Depth
Last trade - 16.10pm 14/10/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.